A new round of correspondence in The Lancet has reopened a methodological debate over the SCIENCE trial, a landmark study on pediatric medial epicondyle fractures. Critics argue the trial's primary endpoint—the PROMIS Pediatric Upper Extremity Computer Adaptive Test—is too broad, lacking elbow-specific items needed to assess critical outcomes like valgus stability and high-demand sport performance.
Trial investigators acknowledged the value of an elbow-specific patient-reported outcome instrument but stated that no such validated tool currently exists for this indication. They defended their choice of the PROMIS measure as prespecified, validated, and supported by patient involvement. The exchange highlights a fundamental tension in surgical research between available measurement tools and clinically meaningful endpoints.
The core dispute centers on functional relevance. While the PROMIS test gauges daily living activities—such as buttoning clothes or opening jars—critics contend that these metrics miss what matters most for displaced fractures: pain under valgus stress, ulnar nerve symptoms, and confidence returning to gymnastics or throwing sports. The trial's conclusions, they warn, may overreach what its primary outcome can legitimately support.
For orthopedic surgeons and families weighing operative versus nonoperative treatment, this debate has practical stakes. Without an elbow-specific measure, future trials may struggle to resolve whether surgery improves high-demand performance or merely hastens return to routine activities. The field now faces a clear call to develop and validate such an instrument in children.
One correspondent noted that the current tool captures capabilities irrelevant to the key clinical uncertainties driving operative decisions for these fractures.